The cardiovascular protection offered by GLP-1 receptor agonists stems from several complementary mechanisms: Anti-inflammatory effects through suppression of CRP, TNF-, and other inflammatory markers Substantial weight reduction, particularly with higher doses of newer agents Blood pressure modulation via direct vascular effects and enhanced natriuresis Improved endothelial function and lipid profiles Renal protective effects, including reduced albuminuria and slowed eGFR decline Though initially established in type 2 diabetes populations, recent evidence from the SELECT trial confirms these benefits extend to non-diabetic patients with obesity and established cardiovascular disease
Tirzepatide is a dual agonist, binding both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Discontinuation of anti-TNFs has been also reported in patients with BD
Patients also face indirect costs, including additional leave from work, extended waiting periods, and potential deterioration in their health condition
Glucagon, released when blood sugars are low, raises them